This study tests two medicines, Cabotegravir and Rilpivirine, for children with HIV-1, ages 2 to less than 12 who are already on HIV treatment. The study will check how the medicines work in the body, their safety, and if they are easy to use. First, the children will take the medicines by mouth, then they will get long-lasting shots. The goal is to find out the best dose based on the child's weight.

To join, the child must have taken their current HIV medicine for at least six months and be healthy enough for the study. The child can't join if they've had certain health issues or medicine reactions. Parents or guardians must agree to let their child participate, and they themselves might answer some questions during the study.

• Study Length: Participants will first take oral medicine, then switch to injections.
• Eligibility: Children must be between 2 and less than 12 years old, already on stable HIV treatment.
• Risks and Compensation: Safety will be monitored. Compensation details, if any, are not specified.

This study helps researchers understand how these medicines work in young children and if they are safe and effective.